Retatrutide vs Tirzepatide: How They Compare

Retatrutide vs tirzepatide: receptor targets, reported weight-loss results, side effects and regulatory status compared side by side.

Signal IQ Editorial4 min read · Updated Nov 8, 2026
Retatrutide vs Tirzepatide: How They Compare
In this article
  1. Retatrutide vs tirzepatide: the side-by-side
  2. Is retatrutide better than tirzepatide?
  3. How the mechanisms differ
  4. Retatrutide vs tirzepatide weight loss
  5. Retatrutide vs tirzepatide side effects
  6. Switching from tirzepatide to retatrutide
  7. What the comparison means in practice
  8. Frequently asked questions
  9. References

Retatrutide vs tirzepatide comes down to receptors and regulatory status. Tirzepatide activates two (GLP-1 and GIP) and is an approved prescription drug. Retatrutide adds a third target, glucagon, and is still investigational. No published head-to-head trial exists yet, so any comparison relies on separate studies.

Key takeaways
  • Tirzepatide is a dual GLP-1/GIP agonist and an approved drug. Retatrutide is a triple GLP-1/GIP/glucagon agonist and is not FDA-approved.
  • The glucagon component is the main difference: it is thought to raise energy expenditure and fat oxidation on top of appetite suppression.
  • In a peer-reviewed phase 2 trial, retatrutide 12 mg produced 24.2% mean weight loss at 48 weeks. No head-to-head trial against tirzepatide has been published.
  • Both cause gastrointestinal side effects, and retatrutide also raises resting heart rate in a dose-dependent way.

Retatrutide vs tirzepatide: the side-by-side

FeatureTirzepatideRetatrutide
Receptor targetsGLP-1 and GIPGLP-1, GIP and glucagon
Regulatory statusApproved prescription drugInvestigational, not FDA-approved
Main actionsAppetite suppression, slower gastric emptying, improved insulin releaseSame, plus higher energy expenditure and fat oxidation via glucagon signalling
Head-to-head trialNone published yet
Common side effectsNausea and other GI effectsNausea and other GI effects, plus rising resting heart rate
Evidence baseLarge approved-drug programmeTrial data still maturing

Is retatrutide better than tirzepatide?

It is too early to say. Efficacy is only one axis, and without a head-to-head trial, cross-study comparisons are unreliable because populations, doses and durations differ. Regulatory status, long-term safety data and tolerability matter just as much.

Tirzepatide has a large body of approved-drug evidence behind it. Retatrutide has promising early results and far less long-term safety data.

How the mechanisms differ

GLP-1

Both compounds act here. GLP-1 signalling reduces appetite, slows gastric emptying and improves glucose-dependent insulin release.

GIP

Both compounds also act on GIP. It appears to work alongside GLP-1 on insulin sensitivity and fat metabolism, which is why dual agonists outperformed GLP-1-only drugs.

Glucagon

Only retatrutide targets this receptor. Glucagon signalling prompts the liver to release stored glycogen, stimulates fat oxidation and raises resting metabolic rate through thermogenesis. The expectation is that the GLP-1/GIP side keeps blood sugar controlled while the glucagon side increases energy use. For a plain-language walkthrough, see how retatrutide works.

Retatrutide vs tirzepatide weight loss

The best peer-reviewed retatrutide figure comes from a phase 2 trial (Jastreboff et al., NEJM 2023), where the 12 mg dose produced a mean weight loss of 24.2% at 48 weeks. Tirzepatide’s approved-drug trials report substantial weight loss too, but they used different populations and durations, so the numbers cannot be lined up directly.

Signal IQ’s compound page also notes that 8 mg and 12 mg produced nearly identical fat loss, with more side effects at the higher dose, which suggests a ceiling to the benefit. Weight lost in trials includes some lean mass, and body composition outcomes vary.

For the wider three-way picture, see semaglutide vs tirzepatide vs retatrutide and peptides for weight loss.

Retatrutide vs tirzepatide side effects

Both are associated with nausea and other gastrointestinal effects, mostly during dose escalation. How the rates compare is unclear without a direct trial.

Retatrutide has an additional point to monitor. Research notes describe resting heart rate rising in a dose-dependent way, peaking several beats per minute above baseline at higher doses, and arriving months into use. Gastrointestinal effects were roughly twice as common in people who started at a high dose than in those who escalated gradually from a low dose.

  • Appetite can be suppressed strongly, so adequate protein and calories matter.
  • Stopping abruptly is associated with rebound hunger.
  • A resting heart rate climbing well above personal baseline is a reason to pause and reassess.

More detail is in peptide side effects.

Switching from tirzepatide to retatrutide

Switching between the two is not a one-to-one conversion. Tirzepatide dose levels do not map onto retatrutide, and the two have different receptor profiles. In research settings, a new compound is generally started again at the bottom of its own escalation, not at an equivalent dose.

Ranges reported in Signal IQ’s research protocols for retatrutide start at 0.5 mg per injection, three times weekly, move to 0.8 mg, and reach a working level around 1.0 mg three times weekly (about 3 mg per week), escalating no faster than every two weeks. Full detail is on the retatrutide research page and the dosage chart. Anyone currently on a prescribed medicine should discuss any change with a qualified clinician, since retatrutide is not an approved treatment.

Note: Retatrutide is not approved for human use and is sold for research purposes only. See whether retatrutide is FDA-approved and research use vs human use.

What the comparison means in practice

  • If the question is evidence depth and regulatory standing, tirzepatide leads clearly.
  • If the question is mechanism and potential maximum effect, retatrutide’s third receptor is the interesting variable.
  • If the question is tolerability, both need slow escalation, and retatrutide adds cardiovascular monitoring.

To explore options by goal, use peptides by goal, or ask Pulse. Baseline labs can be planned with the Bloodwork Panel Planner.

Frequently asked questions

What is the difference between retatrutide and tirzepatide?

Tirzepatide activates GLP-1 and GIP receptors. Retatrutide activates those two plus the glucagon receptor, which is linked to higher energy expenditure.

Is retatrutide stronger than tirzepatide?

Unknown. Retatrutide 12 mg gave 24.2% mean weight loss at 48 weeks in phase 2, but no head-to-head trial has been published.

Is retatrutide FDA-approved?

No. Retatrutide is investigational. Tirzepatide is an approved prescription drug.

Do both cause nausea?

Yes. Nausea and other GI effects are the most common, usually during dose escalation and easing with slower titration.

Can you switch from tirzepatide to retatrutide?

There is no validated conversion. Research protocols restart escalation at the lowest step, and any switch should involve a qualified clinician.

References

  1. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity, phase 2 trial. N Engl J Med, 2023.

Go deeper on Signal IQ

Dosing & protocolRetatrutide

Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.

Ask Pulse

Educational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.

Keep reading